FULC

4.35

7.94% 0.32

Dopo l'orario di chiusura: 4.35

Fulcrum Therapeutics Inc (FULC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.03

Aprire:

$3.99

Volume 24 ore:

2.61M

Relative Volume:

2.61

Capitalizzazione di mercato:

$234.63M

Reddito:

$2.81M

Utile/perdita netta:

$-97.34M

Rapporto P/E:

-2.4167

EPS:

-1.8

Flusso di cassa netto:

$-91.47M

1 W Prestazione:

+9.85%

1M Prestazione:

+45.48%

6M Prestazione:

-31.82%

1 anno Prestazione:

-22.60%

Intervallo 1D:

$3.955

$4.39

Intervallo di 1 settimana:

$3.94

$4.64

Portata 52W:

$2.86

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Nome

Fulcrum Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

617-651-8851

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

Cinguettio

@fulcrumtx

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

FULC's Discussions on Twitter

Confronta FULC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FULC Fulcrum Therapeutics Inc	4.35	234.63M	2.81M	-97.34M	-91.47M	-1.58
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-09-13	Downgrade	H.C. Wainwright	Buy → Neutral
2024-09-12	Downgrade	BofA Securities	Neutral → Underperform
2024-09-12	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2024-09-12	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-12	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-09-12	Downgrade	Stifel	Buy → Hold
2024-09-09	Aggiornamento	BofA Securities	Underperform → Neutral
2024-05-20	Iniziato	Cantor Fitzgerald	Overweight
2024-03-13	Iniziato	RBC Capital Mkts	Outperform
2023-09-25	Iniziato	Goldman	Neutral
2023-08-23	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-08-22	Aggiornamento	Stifel	Hold → Buy
2023-05-04	Downgrade	Goldman	Buy → Neutral
2023-03-10	Downgrade	Credit Suisse	Outperform → Neutral
2023-03-10	Downgrade	H.C. Wainwright	Buy → Neutral
2023-03-09	Downgrade	Stifel	Buy → Hold
2023-02-28	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-02-24	Downgrade	BofA Securities	Neutral → Underperform
2022-11-15	Iniziato	Goldman	Buy
2022-03-08	Iniziato	Oppenheimer	Outperform
2022-03-03	Aggiornamento	BofA Securities	Underperform → Neutral
2021-08-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-22	Iniziato	Credit Suisse	Outperform
2021-03-02	Iniziato	Stifel	Buy
2020-10-16	Iniziato	Piper Sandler	Overweight
2020-08-12	Downgrade	BofA Securities	Neutral → Underperform
2020-08-12	Reiterato	H.C. Wainwright	Buy
2020-08-12	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-06-19	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-17	Iniziato	BTIG Research	Buy
2019-10-03	Iniziato	H.C. Wainwright	Buy
2019-08-12	Iniziato	BofA/Merrill	Buy

Mostra tutto

Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie

Dec 19, 2024

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World

Dec 18, 2024

Dec 17, 2024

Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 17, 2024

Dec 16, 2024

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online

Dec 16, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com

Dec 16, 2024

Dec 15, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Dec 15, 2024

Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC - MarketBeat

Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC - Defense World

Dec 13, 2024

Dec 12, 2024

Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St

Dec 12, 2024

Dec 10, 2024

Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 10, 2024

Dec 06, 2024

BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc. - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces challenges after trial setback - Investing.com Nigeria

Dec 05, 2024

RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 05, 2024

Nov 30, 2024

Braidwell LP Acquires New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024

Connor Clark & Lunn Investment Management Ltd. Makes New $474,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024

Nov 29, 2024

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why - MSN

Nov 29, 2024

Suvretta Capital Management LLC Sells 1,358,255 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 29, 2024

Nov 27, 2024

Fulcrum Therapeutics to Participate in Upcoming December Conferences - The Manila Times

Nov 27, 2024

Nov 26, 2024

Fulcrum Therapeutics to Present at Three Major Healthcare Conferences in December | FULC Stock News - StockTitan

Nov 26, 2024

Nov 21, 2024

CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz

Nov 21, 2024

Nov 20, 2024

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat

Nov 20, 2024

Nov 19, 2024

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail

Nov 19, 2024

Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada

Nov 19, 2024

Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 15, 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024